表紙
市場調查報告書

多發性囊胞腎(PKD)- 市場洞察,流行病學,市場預測 2028年

Polycystic Kidney Disease (PKD) - Market Insights, Epidemiology and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 401847
出版日期 內容資訊 英文 153 Pages
商品交期: 最快1-2個工作天內
價格
多發性囊胞腎(PKD)- 市場洞察,流行病學,市場預測 2028年 Polycystic Kidney Disease (PKD) - Market Insights, Epidemiology and Market Forecast-2028
出版日期: 2019年09月01日內容資訊: 英文 153 Pages
簡介

主要新興國家(中國、台灣、沙烏地阿拉伯、阿拉伯聯合大公國、俄羅斯、土耳其、哥倫比亞、巴西、阿根廷、墨西哥)的多發性囊胞腎(PKD)2017年的市場規模估算為8,320萬美元,患病數191萬2,820人估計。

本報告提供主要新興國家(中國、台灣、沙烏地阿拉伯、阿拉伯聯合大公國、俄羅斯、土耳其、哥倫比亞、巴西、阿根廷、墨西哥)的多發性囊胞腎(PKD)市場調查,市場及疾病概要,類型(多發性囊胞腎、平常染色體優性多發性囊胞腎)、各國流行病學的預測,現行治療,未滿足需求,新藥概要,以整體及各國的市場規模的變化與預測,市場成長要素及障礙分析等資料彙整。

目錄

第1章 重要洞察

第2章 多發性囊胞腎(PKD)的市場概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第3章 多發性囊胞腎(PKD):疾病背景和概要

  • 簡介
  • 類型
  • 原因
  • 危險因素
  • 徵兆與症狀
  • 病理生理學
  • 診斷
  • 生物標記
  • 多發性囊胞腎(PKD)的併發症

第4章 流行病學及患者人口:各地區

  • 主要調查結果
  • 關鍵意見領袖的意見

第5章 新興國家(前十名國家)的多發性囊胞腎(PKD)患病數

  • 多發性囊胞腎(PKD)的總患病數
  • 平常染色體優性多發性囊胞腎(AD-PKD)的患病數

第6章 多發性囊胞腎(PKD)的流行病學:各地區

  • 亞洲、東歐
    • 中國
    • 台灣
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 俄羅斯
    • 土耳其
  • 南美
    • 哥倫比亞
    • 巴西
    • 阿根廷
    • 墨西哥

第7章 多發性囊胞腎(PKD)的治療和管理

第8章 未滿足需求

第9章 新藥

  • Tolvaptan:大塚製藥
    • 產品說明
    • 產品的開發趨勢
    • 安全性和有效性
    • 產品簡介
  • Bardoxolone methyl: Reata Pharmaceuticals, Inc.
  • Venglustat:Sanofi Genzyme

第10章 多發性囊胞腎(PKD):新興國家(前十名國家)分析

  • 主要調查結果
  • 關鍵意見領袖分析
  • 主要新興國家的市場規模
    • 市場規模:各治療藥物

第11章 各國市場預測

  • 新興國家市場預測
  • 中國
    • 多發性囊胞腎(PKD)的總市場規模
    • 多發性囊胞腎(PKD)的市場規模:各治療藥物
  • 台灣
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 土耳其
  • 俄羅斯
  • 哥倫比亞
  • 巴西
  • 阿根廷
  • 墨西哥

第12章 市場成長要素

第13章 市場障礙

第14章 附錄

  • 報告方法

第15章 DelveInsight的服務內容

第16章 免責聲明

第17章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0169

DelveInsight's 'Polycystic Kidney Disease (PKD)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PKDs in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Polycystic Kidney Disease (PKD) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)

Study Period: 2017-2028

Polycystic Kidney Disease (PKD) - Disease Understanding and Treatment Algorithm

Polycystic kidney disease (PKD) is part of a heterogeneous group of disorders characterized by renal cysts and numerous systemic and extrarenal manifestations. In patients with PKD, the kidneys contain multiple fluid-filled cysts. People with PKD can also have cysts in the liver (mainly) and problems in other organs, such as the heart and blood vessels in the brain. Although PKD is inherited monogenically, it is phenotypically, genetically, and allelically heterogeneous.

The DelveInsight Polycystic Kidney Disease (PKD) market report gives the thorough understanding of the Polycystic Kidney Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Polycystic Kidney Disease in Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Polycystic Kidney Disease Epidemiology

The Polycystic Kidney Disease (PKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients) scenario of Polycystic Kidney Disease (PKD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Polycystic Kidney Disease (PKD) in 10 EM was found to be 1,912,820, in the year 2017.

Polycystic Kidney Disease Drug Chapters

This segment of the Polycystic Kidney Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast focuses on the market revenue generated by the pharmacological treatment which are primarily symptomatic or palliative in nature. Antihypertensive drugs to slow the deterioration of Renal Function, Antibiotics to treat UTI or infected renal cysts and Analgesics to control renal pain. Immunosuppresants from another important class of drugs used only in patients undergoing Renal Transplant. It is to be noted that only a small fraction of the entire diagnosed PKD patient pool can opt for or are eligible for undergoing such surgical interventions. Therefore immunosuppressant drugs constitute a significantly lesser amount of share as compared to other supportive therapies.

Polycystic Kidney Disease Market Outlook

The Polycystic Kidney Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Polycystic Kidney Disease in 10EM was found to be USD 83.2 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Polycystic Kidney Disease, in comparison to Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, and Taiwan.

Polycystic Kidney Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Polycystic Kidney Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Polycystic Kidney Disease Report Key Strengths

  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Polycystic Kidney Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Polycystic Kidney Disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Polycystic Kidney Disease market
  • To understand the future market competition in the Polycystic Kidney Disease market.

Table of Contents

1. Key Insights

2. PKD Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of PKD in 2017
  • 2.2. Market Share (%) Distribution of PKD in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Signs and symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
  • 3.8. Biomarkers
  • 3.9. Other Complications associated with PKD

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings
  • 4.2. KOL views

5. Ten Emerging Markets (EM) Total Prevalent Population of Polycystic kidney disease (PKD)

  • 5.1. Total Prevalence of PKD in 10 Emerging Markets
  • 5.2. Prevalence of AD-PKD in 10 Emerging Markets

6. Region Wise-Epidemiology of Polycystic kidney disease (PKD)

  • 6.1. Asia and East Europe (China, Taiwan, Saudi Arabia, UAE, Russia, and Turkey)
    • 6.1.1. Assumptions and Rationale:
      • 6.1.1.1. China
      • 6.1.1.2. Total Prevalent Cases of PKD in China
      • 6.1.1.2.1. Prevalence of PKD by Types in China
      • 6.1.1.2.2. Prevalent Cases of PKD by Gender in China
      • 6.1.1.2.3. Diagnosed Prevalence of PKD in China
      • 6.1.1.2.4. Clinical Manifestations in Patients of ADPKD in China
      • 6.1.1.2.5. Transplant Eligible PKD Patients in China
      • 6.1.1.3. Taiwan
      • 6.1.1.3.1. Total Prevalent Cases of PKD in Taiwan
      • 6.1.1.3.2. Prevalence of PKD by Types in Taiwan
      • 6.1.1.3.3. Prevalent Cases of PKD by Gender in Taiwan
      • 6.1.1.3.4. Diagnosed Prevalence of PKD in Taiwan
      • 6.1.1.3.5. Clinical Manifestations in Patients of ADPKD in Taiwan
      • 6.1.1.3.6. Transplant Eligible PKD Patients in Taiwan
      • 6.1.1.4. Saudi Arabia
      • 6.1.1.4.1. Total Prevalent Cases of PKD in Saudi Arabia
      • 6.1.1.4.2. Prevalence of PKD by Types in Saudi Arabia
      • 6.1.1.4.3. Prevalent Cases of PKD by Gender in Saudi Arabia
      • 6.1.1.4.4. Diagnosed Prevalence of PKD in Saudi Arabia
      • 6.1.1.4.5. Clinical Manifestations in Patients of ADPKD in Saudi Arabia
      • 6.1.1.4.6. Transplant Eligible PKD Patients in Saudi Arabia
      • 6.1.1.5. UAE
      • 6.1.1.5.1. Total Prevalent Cases of PKD in UAE
      • 6.1.1.5.2. Prevalence of PKD by Types in UAE
      • 6.1.1.5.3. Prevalent Cases of PKD by Gender in UAE
      • 6.1.1.5.4. Diagnosed Prevalence of PKD in UAE
      • 6.1.1.5.5. Clinical Manifestations in Patients of ADPKD in UAE
      • 6.1.1.5.6. Transplant Eligible PKD Patients in UAE
      • 6.1.1.6. Turkey
      • 6.1.1.6.1. Total Prevalent Cases of PKD in Turkey
      • 6.1.1.6.2. Prevalence of PKD by Types in Turkey
      • 6.1.1.6.3. Prevalent Cases of PKD by Gender in Turkey
      • 6.1.1.6.4. Diagnosed Prevalence of PKD in Turkey
      • 6.1.1.6.5. Clinical Manifestations in Patients of ADPKD in Turkey
      • 6.1.1.6.6. Transplant Eligible PKD Patients in Turkey
      • 6.1.1.7. Russia
      • 6.1.1.7.1. Total Prevalent Cases of PKD in Russia
      • 6.1.1.7.2. Prevalence of PKD by Types in Russia
      • 6.1.1.7.3. Prevalent Cases of PKD by Gender in Russia
      • 6.1.1.7.4. Diagnosed Prevalence of PKD in Russia
      • 6.1.1.7.5. Clinical Manifestations in Patients of ADPKD in Russia
      • 6.1.1.7.6. Transplant Eligible PKD Patients in Russia
  • 6.2. LATAM (Colombia, Brazil, Argentina, and Mexico)
    • 6.2.1. Assumptions and Rationale:
      • 6.2.1.1. Colombia
      • 6.2.1.1.1. Total Prevalent Cases of PKD in Colombia
      • 6.2.1.1.2. Prevalence of PKD by Types in Colombia
      • 6.2.1.1.3. Prevalent Cases of PKD by Gender in Colombia
      • 6.2.1.1.4. Diagnosed Prevalence of PKD in Colombia
      • 6.2.1.1.5. Clinical Manifestations in Patients of ADPKD in Colombia
      • 6.2.1.1.6. Transplant Eligible PKD Patients in Colombia
      • 6.2.1.2. Brazil
      • 6.2.1.2.1. Total Prevalent Cases of PKD in Brazil
      • 6.2.1.2.2. Prevalence of PKD by Types in Brazil
      • 6.2.1.2.3. Prevalent Cases of PKD by Gender in Brazil
      • 6.2.1.2.4. Diagnosed Prevalence of PKD in Brazil
      • 6.2.1.2.5. Clinical Manifestations in Patients of ADPKD in Brazil
      • 6.2.1.2.6. Transplant Eligible PKD Patients in Brazil
      • 6.2.1.3. Argentina
      • 6.2.1.3.1. Total Prevalent Cases of PKD in Argentina
      • 6.2.1.3.2. Prevalence of PKD by Types in Argentina
      • 6.2.1.3.3. Prevalent Cases of PKD by Gender in Argentina
      • 6.2.1.3.4. Diagnosed Prevalence of PKD in Argentina
      • 6.2.1.3.5. Clinical Manifestations in Patients of ADPKD in Argentina
      • 6.2.1.3.6. Transplant Eligible PKD Patients in Argentina
      • 6.2.1.4. Mexico
      • 6.2.1.4.1. Total Prevalent Cases of PKD in Mexico
      • 6.2.1.4.2. Prevalence of PKD by Types in Mexico
      • 6.2.1.4.3. Prevalent Cases of PKD by Gender in Mexico
      • 6.2.1.4.4. Diagnosed Prevalence of PKD in Mexico
      • 6.2.1.4.5. Clinical Manifestations in Patients of ADPKD in Mexico
      • 6.2.1.4.6. Transplant Eligible PKD Patients in Mexico

7. Treatment and Management of Polycystic Kidney Disease

8. Unmet Needs

9. Emerging Therapies

  • 9.1. Tolvaptan: Otsuka Pharmaceutical Co., Ltd.
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Safety and Efficacy
    • 9.1.4. Product Profile
  • 9.2. Bardoxolone methyl: Reata Pharmaceuticals, Inc.
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
      • 9.2.3.1. Clinical Trials Information
    • 9.2.4. Safety and Efficacy
    • 9.2.5. Product Profile
  • 9.3. Venglustat: Sanofi Genzyme
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
      • 9.3.3.1. Clinical Trials Information
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile

10. Polycystic kidney disease (PKD): 10 EM Analysis

  • 10.1. Key Findings
  • 10.2. KOL Views
  • 10.3. Market Size of Polycystic kidney disease (PKD) in 10 EM
    • 10.3.1. Market Size of PKD by Therapies

11. Market Outlook by Country

  • 11.1. Emerging Markets: Market Outlook
  • 11.2. China
    • 11.2.1. Total Market Size of Polycystic kidney disease
    • 11.2.2. Market Size of Polycystic kidney disease by Therapies
  • 11.3. Taiwan
    • 11.3.1. Total Market Size of Polycystic kidney disease
    • 11.3.2. Market Size of Polycystic kidney disease by Therapies
  • 11.4. Saudi Arabia
    • 11.4.1. Total Market Size of Polycystic kidney disease
    • 11.4.2. Market Size of Polycystic kidney disease by Therapies
  • 11.5. UAE
    • 11.5.1. Total Market Size of Polycystic kidney disease
    • 11.5.2. Market Size of Polycystic kidney disease by Therapies
  • 11.6. Turkey
    • 11.6.1. Total Market Size of Polycystic kidney disease
    • 11.6.2. Market Size of Polycystic kidney disease by Therapies
  • 11.7. Russia
    • 11.7.1. Total Market Size of Polycystic kidney disease
    • 11.7.2. Market Size of Polycystic kidney disease by Therapies
  • 11.8. Colombia
    • 11.8.1. Total Market Size of Polycystic kidney disease
    • 11.8.2. Market Size of Polycystic kidney disease by Therapies
  • 11.9. Brazil
    • 11.9.1. Total Market Size of Polycystic kidney disease
    • 11.9.2. Market Size of Polycystic kidney disease by Therapies
  • 11.10. Argentina
    • 11.10.1. Total Market Size of Polycystic kidney disease
    • 11.10.2. Market Size of Polycystic kidney disease by Therapies
  • 11.11. Mexico
    • 11.11.1. Total Market Size of Polycystic kidney disease
    • 11.11.2. Market Size of Polycystic kidney disease by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Tables

  • Table 1: Total Prevalence of PKD in 10 Emerging Markets (2017-2028)
  • Table 2: Diagnosed Prevalence of ADPKD in 10 Emerging Markets (2017-2028)
  • Table 3: Total Prevalence Cases of PKD in China (2017-2028)
  • Table 4: Prevalence of PKD by Types in China (2017-2028)
  • Table 5: Prevalence of PKD by Gender in China (2017-2028)
  • Table 6: Diagnosed Prevalence of PKD in China (2017-2028)
  • Table 7: Clinical Manifestations in Patients of ADPKD in China (2017-2028)
  • Table 8: Transplant Eligible PKD Patients in China (2017-2028)
  • Table 9: Total Prevalence Cases of PKD in Taiwan (2017-2028)
  • Table 10: Prevalence of PKD by Types in Taiwan (2017-2028)
  • Table 11: Prevalence of PKD by Gender in Taiwan (2017-2028)
  • Table 12: Diagnosed Prevalence of PKD in Taiwan (2017-2028)
  • Table 13: Clinical Manifestations in Patients of ADPKD in Taiwan (2017-2028)
  • Table 14: Transplant Eligible PKD Patients in Taiwan (2017-2028)
  • Table 15: Total Prevalence Cases of PKD in Saudi Arabia (2017-2028)
  • Table 16: Prevalence of PKD by Types in Saudi Arabia (2017-2028)
  • Table 17: Prevalence of PKD by Gender in Saudi Arabia (2017-2028)
  • Table 18: Diagnosed Prevalence of PKD in Saudi Arabia (2017-2028)
  • Table 19: Clinical Manifestations in Patients of ADPKD in Saudi Arabia (2017-2028)
  • Table 20: Transplant Eligible PKD Patients in Saudi Arabia (2017-2028)
  • Table 21: Total Prevalence Cases of PKD in UAE (2017-2028)
  • Table 22: Prevalence of PKD by Types in UAE (2017-2028)
  • Table 23: Prevalence of PKD by Gender in UAE (2017-2028)
  • Table 24: Diagnosed Prevalence of PKD in UAE (2017-2028)
  • Table 25: Clinical Manifestations in Patients of ADPKD in UAE (2017-2028)
  • Table 26: Transplant Eligible PKD Patients in UAE ( (2017-2028)
  • Table 27: Total Prevalence Cases of PKD in Turkey (2017-2028)
  • Table 28: Prevalence of PKD by Types in Turkey (2017-2028)
  • Table 29: Prevalence of PKD by Gender in Turkey (2017-2028)
  • Table 30: Diagnosed Prevalence of PKD in Turkey (2017-2028)
  • Table 31: Clinical Manifestations in Patients of ADPKD in Turkey (2017-2028)
  • Table 32: Transplant Eligible PKD Patients in Turkey (2017-2028)
  • Table 33: Total Prevalence Cases of PKD in Russia (2017-2028)
  • Table 34: Prevalence of PKD by Types in Russia (2017-2028)
  • Table 35: Prevalence of PKD by Gender in Russia (2017-2028)
  • Table 36: Diagnosed Prevalence of PKD in Russia (2017-2028)
  • Table 37: Clinical Manifestations in Patients of ADPKD in Russia (2017-2028)
  • Table 38: Transplant Eligible PKD Patients in Russia (2017-2028)
  • Table 39: Total Prevalence Cases of PKD in Colombia (2017-2028)
  • Table 40: Prevalence of PKD by Types in Colombia (2017-2028)
  • Table 41: Prevalence of PKD by Gender in Colombia (2017-2028)
  • Table 42: Diagnosed Prevalence of PKD in Colombia (2017-2028)
  • Table 43: Clinical Manifestations in Patients of ADPKD in Colombia (2017-2028)
  • Table 44: Transplant Eligible PKD Patients in Colombia (2017-2028)
  • Table 45: Total Prevalence Cases of PKD in Brazil (2017-2028)
  • Table 46: Prevalence of PKD by Types in Brazil (2017-2028)
  • Table 47: Prevalence of PKD by Gender in Brazil (2017-2028)
  • Table 48: Diagnosed Prevalence of PKD in Brazil (2017-2028)
  • Table 49: Clinical Manifestations in Patients of ADPKD in Brazil (2017-2028)
  • Table 50: Transplant Eligible PKD Patients in Brazil (2017-2028)
  • Table 51: Total Prevalence Cases of PKD in Argentina (2017-2028)
  • Table 52: Prevalence of PKD by Types in Argentina (2017-2028)
  • Table 53: Prevalence of PKD by Gender in Argentina (2017-2028)
  • Table 54: Diagnosed Prevalence of PKD in Argentina (2017-2028)
  • Table 55: Clinical Manifestations in Patients of ADPKD in Argentina (2017-2028)
  • Table 56: Transplant Eligible PKD Patients in Argentina (2017-2028)
  • Table 57: Total Prevalence Cases of PKD in Mexico (2017-2028)
  • Table 58: Prevalence of PKD by Types in Mexico (2017-2028)
  • Table 59: Prevalence of PKD by Gender in Mexico (2017-2028)
  • Table 60: Diagnosed Prevalence of PKD in Mexico (2017-2028)
  • Table 61: Clinical Manifestations in Patients of ADPKD in Mexico (2017-2028)
  • Table 62: Transplant Eligible PKD Patients in Mexico (2017-2028)
  • Table 63: Total Market Size of PKD in 10 Emerging Markets in USD Million (2017-2028)
  • Table 64: Total Market Size of PKD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Table 65: Total Market Size of PKD in China, USD Million (2017-2028)
  • Table 66: China Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 67: Total Market Size of PKD in Taiwan, USD Million (2017-2028)
  • Table 68: Taiwan Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 69: Total Market Size of PKD in Saudi Arabia, USD Million (2017-2028)
  • Table 70: Saudi Arabia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 71: Total Market Size of PKD in UAE, USD Million (2017-2028)
  • Table 72: UAE Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 73: Total Market Size of PKD in Turkey, USD Million (2017-2028)
  • Table 74: Turkey Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 75: Total Market Size of PKD in Russia, USD Million (2017-2028)
  • Table 76: Russia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 77: Total Market Size of PKD in Colombia, USD Million (2017-2028)
  • Table 78: Colombia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 79: Total Market Size of PKD in Brazil, USD Million (2017-2028)
  • Table 80: Brazil Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 81: Total Market Size of PKD in Argentina, USD Million (2017-2028)
  • Table 82: Argentina Market Size of PKD by Therapies in USD Million (2017-2028)
  • Table 83: Total Market Size of PKD in Mexico, USD Million (2017-2028)
  • Table 84: Mexico Market Size of PKD by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Polycystic kidney disease Signs and symptoms
  • Figure 2: Domain organization of proteins implicated in polycystic kidney disease
  • Figure 3: Mechanisms of cyst formation and expansion: a) PCI-PC2 localization b) ciliary localization of the polycystins
  • Figure 4: Renal fibrosis in autosomal dominant polycystic kidney disease
  • Figure 5: Renal fibrosis in autosomal dominant polycystic kidney disease
  • Figure 6: Ultrasonography criteria for an ADPKD diagnosis in at-risk individual
  • Figure 7: Potential Biomarkers in polycystic kidney disease
  • Figure 9: Total Prevalence of PKD in 10 Emerging Markets (2017-2028)
  • Figure 10: Diagnosed Prevalence of ADPKD in 10 Emerging Markets (2017-2028)
  • Figure 11: Total Prevalence Cases of PKD in China (2017-2028)
  • Figure 12: Prevalence of PKD by Types in China (2017-2028)
  • Figure 13: Prevalent Cases by gender of PKD in China (2017-2028)
  • Figure 14: Diagnosed Prevalence of PKD in China (2017-2028)
  • Figure 15: Clinical Manifestations in Patients of ADPKD in China (2017-2028)
  • Figure 16: Transplant Eligible PKD Patients in China (2017-2028)
  • Figure 17: Total Prevalence Cases of PKD in Taiwan (2017-2028)
  • Figure 18: Prevalence of PKD by Types in Taiwan (2017-2028)
  • Figure 19: Prevalent Cases by gender of PKD in Taiwan (2017-2028)
  • Figure 20: Diagnosed Prevalence of PKD in Taiwan (2017-2028)
  • Figure 21: Clinical Manifestations in Patients of ADPKD in Taiwan (2017-2028)
  • Figure 22: Transplant Eligible PKD Patients in Taiwan (2017-2028)
  • Figure 23: Total Prevalence Cases of PKD in Saudi Arabia (2017-2028)
  • Figure 24: Prevalence of PKD by Types in Saudi Arabia (2017-2028)
  • Figure 25: Prevalent Cases by gender of PKD in Saudi Arabia (2017-2028)
  • Figure 26: Diagnosed Prevalence of PKD in Saudi Arabia (2017-2028)
  • Figure 27: Clinical Manifestations in Patients of ADPKD in Saudi Arabia (2017-2028)
  • Figure 28: Transplant Eligible PKD Patients in Saudi Arabia (2017-2028)
  • Figure 29: Total Prevalence Cases of PKD in UAE (2017-2028)
  • Figure 30: Prevalence of PKD by Types in UAE (2017-2028)
  • Figure 31: Prevalent Cases by gender of PKD in UAE (2017-2028)
  • Figure 32: Diagnosed Prevalence of PKD in UAE (2017-2028)
  • Figure 33: Clinical Manifestations in Patients of ADPKD in UAE (2017-2028)
  • Figure 34: Transplant Eligible PKD Patients in UAE (2017-2028)
  • Figure 35: Total Prevalence Cases of PKD in Turkey (2017-2028)
  • Figure 36: Prevalence of PKD by Types in Turkey (2017-2028)
  • Figure 37: Prevalent Cases by gender of PKD in Turkey (2017-2028)
  • Figure 38: Diagnosed Prevalence of PKD in Turkey (2017-2028)
  • Figure 39: Clinical Manifestations in Patients of ADPKD in Turkey (2017-2028)
  • Figure 40: Transplant Eligible PKD Patients in Turkey (2017-2028)
  • Figure 41: Total Prevalence Cases of PKD in Russia (2017-2028)
  • Figure 42: Prevalence of PKD by Types in Russia (2017-2028)
  • Figure 43: Prevalent Cases by gender of PKD in Russia (2017-2028)
  • Figure 44: Diagnosed Prevalence of PKD in Russia (2017-2028)
  • Figure 45: Clinical Manifestations in Patients of ADPKD in Russia (2017-2028)
  • Figure 46: Transplant Eligible PKD Patients in Russia (2017-2028)
  • Figure 47: Total Prevalence Cases of PKD in Colombia (2017-2028)
  • Figure 48: Prevalence of PKD by Types in Colombia (2017-2028)
  • Figure 49: Prevalent Cases by gender of PKD in Colombia (2017-2028)
  • Figure 50: Diagnosed Prevalence of PKD in Colombia (2017-2028)
  • Figure 51: Clinical Manifestations in Patients of ADPKD in Colombia (2017-2028)
  • Figure 52: Transplant Eligible PKD Patients in Colombia (2017-2028)
  • Figure 53: Total Prevalence Cases of PKD in Brazil (2017-2028)
  • Figure 54: Prevalence of PKD by Types in Brazil (2017-2028)
  • Figure 55: Prevalent Cases by Gender of PKD in Brazil (2017-2028)
  • Figure 56: Diagnosed Prevalence of PKD in Brazil (2017-2028)
  • Figure 57: Clinical Manifestations in Patients of ADPKD in Brazil (2017-2028)
  • Figure 58: Transplant Eligible PKD Patients in Brazil (2017-2028)
  • Figure 59: Total Prevalence Cases of PKD in Argentina (2017-2028)
  • Figure 60: Prevalence of PKD by Types in Argentina (2017-2028)
  • Figure 61: Prevalent Cases by Gender of PKD in Argentina (2017-2028)
  • Figure 62: Diagnosed Prevalence of PKD in Argentina (2017-2028)
  • Figure 63: Clinical Manifestations in Patients of ADPKD in Argentina (2017-2028)
  • Figure 64: Transplant Eligible PKD Patients in Argentina (2017-2028)
  • Figure 65: Total Prevalence Cases of PKD in Mexico (2017-2028)
  • Figure 66: Prevalence of PKD by Types in Mexico (2017-2028)
  • Figure 67: Prevalent Cases by Gender of PKD in Mexico (2017-2028)
  • Figure 68: Diagnosed Prevalence of PKD in Mexico (2017-2028)
  • Figure 69: Clinical Manifestations in Patients of ADPKD in Mexico (2017-2028)
  • Figure 70: Transplant Eligible PKD Patients in Mexico (2017-2028)
  • Figure 71: Unmet Needs of Polycystic Kidney Disease
  • Figure 72: Total Market Size of PKD in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 73: Total Market Size of PKD by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 74: Total Market Size of PKD in China, USD Million (2017-2028)
  • Figure 75: China Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 76: Total Market Size of PKD in Taiwan, USD Million (2017-2028)
  • Figure 77: Taiwan Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 78: Total Market Size of PKD in Saudi Arabia, USD Million (2017-2028)
  • Figure 79: Saudi Arabia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 80: Total Market Size of PKD in UAE, USD Million (2017-2028)
  • Figure 81: UAE Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 82: Total Market Size of PKD in Turkey, USD Million (2017-2028)
  • Figure 83: Turkey Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 84: Total Market Size of PKD in Russia, USD Million (2017-2028)
  • Figure 85: Russia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 86: Total Market Size of PKD in Colombia, USD Million (2017-2028)
  • Figure 87: Colombia Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 88: Total Market Size of PKD in Brazil, USD Million (2017-2028)
  • Figure 89: Brazil Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 90: Total Market Size of PKD in Argentina, USD Million (2017-2028)
  • Figure 91: Argentina Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 92: Total Market Size of PKD in Mexico, USD Million (2017-2028)
  • Figure 93: Mexico Market Size of PKD by Therapies in USD Million (2017-2028)
  • Figure 94: Market Drivers
  • Figure 95: Market Barriers